Newsfiscal.ai
Nexentis Technologies' Subsidiary MitoCareX Bio Completes Initial Computational Screening with Boltz
· Published
Article summary
Nexentis Technologies Inc. announced that its subsidiary, MitoCareX Bio Ltd., has finished the first computational screening phase of its drug-discovery collaboration with AI research lab Boltz, PBC.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…